

【欧文原著】

Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer: comparison with enhanced CT.

Tokunaga S, Koda M, Matono T, Sugihara T, Nagahara T, Ueki M, Murawaki Y, Kakite S, Yamashita E

Br J Radiol 85: 745–752, 2012

Sequential analysis of diethylnitrosamine-induced hepatocarcinogenesis in rats.

Abe R, Okano J, Imamoto R, Fujise Y, Murawaki Y

Exp Ther Med 3: 371–378, 2012

Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice

Kato J, Koda M, Kishina M, Tokunaga S, Matono T, Sugihara T, Ueki M, Murawaki Y

Int J Mol Med 30: 107–113, 2012

Preventive effect of caffeine and curcumin on hepatocarcinogenesis in diethylnitrosamine-induced rats.

Fujise Y, Okano J, Nagahara T, Abe R, Imamoto R, Murawaki Y

Int J Oncol 40: 1779–1788, 2012

Assessment of ablative margin after radiofrequency ablation for hepatocellular carcinoma; comparison between magnetic resonance imaging with ferucarbotran and enhanced CT with iodized iodine deposition

Koda M, Tokunaga S, Fujise Y, Kato J, Matono T, Sugihara T, Nagahara T, Ueki M, Murawaki Y, Kakite S, Yamashita E

Eur J Radiol 81:1400–1404, 2012

Expression of AID, p53, and Mlh1 proteins in endoscopically resected differentiated-type early gastric cancer.

Takeda Y, Yashima K, Hayashi A, Sasaki S, Kawaguchi K, Harada K, Murawaki Y, Ito H

World J Gastrointestinal Oncol 4: 131–137, 2012

Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma.

Koda M, Tokunaga S, Miyoshi K, Kishina M, Fujise Y, Kato J, Matono T, Okamoto K, Murawaki Y, Kakite S

Eur J Radiol 81: 2730–2736, 2012

Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16,346 treated nodules in 13,283 patients.

Koda M, Murawaki Y, Hirooka Y, Kitamoto M, Ono M, Sakaeda H, Joko K, Sato S, Tamaki K, Yamasaki T, Shibata H, Shimoe T, Matsuda T, Toshikuni N, Fujioka S, Ohmoto K, Nakamura S, Kariyama K, Aikata H, Kobayashi Y, Tsutsui A.

Hepatol Res 42: 1058–1064, 2012

Fhit, E-cadherin, p53, and activation-induced cytidine deaminase expression in endoscopically resected early stage esophageal squamous neoplasia.

Hayashi A, Yashima K, Takeda Y, Sasaki S, Kawaguchi K, Harada K, Murawaki Y, Ito H.

J Gastroenterol Hepatol 27: 1752–1758, 2012

Prevalence of organic colonic lesions in patients meeting Rome III criteria for diagnosis of IBS: a prospective multi-center study utilizing colonoscopy.

Ishihara S, Yashima K, Kushiyama Y, Izumi A, Lawashima K, Fujishiro H, Kojo H, Komazawa Y, Hamamoto T, Yamamoto T, Sasaki Y, Shimizu T, Okamoto E, Yoshimura T, Furuta K, Noguchi N, Tanaka H, Murawaki Y, Kinoshita Y

J Gastroenterol 47: 1084–1090, 2012

No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations.

Sawai H, Nishida N, Mbarek H, Matsuda K, Mawatari Y, Yamaoka M, Hige S, Kang JH, Murawaki Y, et al.

BMC Med Genet 13: 47, 2012

Genome-wide association study confirming association of HLA-DR with protection against chronic hepatitis B and viral clearance in Japanese and Korean.

Nishida N, Sawai H, Matsuura K, Sugiyama M, Ahn SH, Park JY, Hige S, Murawaki Y, et al.

PLoS One 7: e39175, 2012

Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.

Takahashi O, Komaki R, Smith PD, Jurgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biemacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS

Clin Cancer Res 18: 1641-1654, 2012

【欧文症例】

Contrast-enhanced sonography with perflubutane revealing active bleeding as a complication of radiofrequency ablation.

Matono T, Koda M, Murawaki Y

Hepatology 55: 649-650, 2012

Right diaphragmatic defect in hepatic hydrothorax exposed by contrast-enhanced ultrasonography after radiofrequency ablation

Matono T, Koda M, Murawaki Y

Hepatology 56: 784-785, 2012

【欧文総説】

The therapeutic potential of RNA interference: novel approaches for cancer treatment.

Okamoto K, Murawaki Y

Curr Pharm Biotechnol 13: 2235-2247, 2012

【和文原著】

肝癌診療ガイドラインによるサーベイランスの実情と問題点

安部良, 岡野淳一, 今本龍, 藤瀬幸, 孝田雅彦, 村脇義和

日本消化器病学会雑誌 109: 741-750, 2012

当院における膵癌の患者・臨床背景とリスクファクターの検討

武田洋平, 八島一夫, 松本和也, 河口剛一郎, 原田賢一, 村脇義和

膵臓 27: 158-166, 2012

山陰地方のゲノタイプ1型かつ高ウイルス量C型慢性肝炎に対するペグインターフェロン α -2bとリバビリン併用療法の治療成績

岡野淳一, 今本龍, 澤田慎太郎, 安部良, 藤瀬幸, 村脇義和

鳥取医誌 40: 178-184, 2012

【和文症例】

強皮症に続発した慢性偽性腸閉塞症に腸管囊腫様気腫・気腹症を合併した1例

林暁洋, 八島一夫, 生田幸広, 今本龍, 佐々木修治, 武田洋平, 池淵雄一郎, 安部良,

松本和也, 香田正晴, 河口剛一郎, 原田賢一, 村脇義和

消化管の臨床 17: 95-99, 2012

健康食品「にんにく卵黄」によると思われる薬物性肝障害の1例

岡本欣也, 三好謙一, 木科学, 藤瀬幸, 加藤順, 徳永志保, 的野智光, 法正恵子, 大

山賢治, 岡野淳一, 前田直人, 孝田雅彦, 村脇義和

肝臓 53: 748-753, 2012

後腹膜線維症による急性腎不全にて発症したIgG4関連疾患の1例

前田佐登子, 宗村千潮, 石田千尋, 福井毅顕, 村脇義和

日内誌 101: 1079-1081, 2012

【和文総説】

特発性細菌性腹膜炎(SBP)のマネジメント(特集:非代償生肝硬変の合併症とその対策)

杉原誉明, 孝田雅彦, 村脇義和
消化器内科 54: 366-372, 2012

血性肝線維化マーカーと肝線維化予測モデル

孝田雅彦
肝胆膵 65: 267-275, 2012

【和文著書】

山陰地方における非 B 非 B 肝硬変の実態

大山賢治, 前田直人, 村脇義和
我が国における非 B 非 B 肝硬変の実態調査 2011 pp 53-57, 2012

当院における急性肝炎の実態

藤瀬幸, 孝田雅彦, 岡野淳一, 村脇義和
わが国における急性肝炎の現状 全国調査 2008-2011 pp141-144, 2012